---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-354053"
form_type: "8-K"
ticker: "AARD"
cik: "0001774857"
company_name: "Aardvark Therapeutics, Inc."
filed_at: "2026-08-17T20:10:31+00:00"
generated_at: "2026-08-17T20:12:22.860343+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Aardvark Therapeutics annual meeting: directors elected, BDO ratified, option repricing approved

## Summary
- Victor Tong Jr. and Jeffrey Chi elected as Class I directors; Tong received 6,264,929 votes for, Chi 6,426,038.
- BDO USA ratified as independent auditor for FY2026 with 11,877,567 votes for.
- Stock option repricing under 2017, 2025, and 2025 Inducement Plans approved with 4,649,269 for, 3,439,983 against.
- Quorum of 54.79% of outstanding shares represented at the meeting.

## SEC filing metadata
- accession: 0001193125-26-354053
- form_type: 8-K
- ticker: AARD
- cik: 0001774857
- company_name: Aardvark Therapeutics, Inc.
- filed_at: 2026-08-17T20:10:31+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1774857/000119312526354053/0001193125-26-354053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1774857/000119312526354053/ck0001774857-20260814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-354053
- JSON: https://secwatch.observer/filing/0001193125-26-354053.json
- Plain text: https://secwatch.observer/filing/0001193125-26-354053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.